DelveInsight’s, “Urothelial Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including Urothelial Carcinoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Urothelial Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Urothelial Carcinoma NDA approvals (if any), and product development activities comprising the technology, Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Urothelial Carcinoma Pipeline Report
To explore more information on the latest breakthroughs in the Urothelial carcinoma Pipeline treatment landscape of the report, click here @ Urothelial carcinoma Pipeline Outlook
Urothelial Carcinoma Overview
Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is by far the most common type of bladder cancer. Urothelial carcinomas are the fourth most common tumors after prostate, lung and colorectal cancer. This carcinoma is derived from the urothelium of the upper urinary tract (renal pelvis and ureter) or lower urinary tract (urinary bladder). In contrast with bladder urothelial carcinomas, upper urinary tract urothelial carcinomas (UTUCs) are relatively rare and account for only 5 to 10% of urothelial carcinomas. Development of targeted therapies for urothelial carcinoma is still in early stages, consequently there have been no major therapeutic advances to date. However, greater understanding of urothelial carcinoma and solid tumor biology has resulted in a proliferation of clinical trials that could lead to significant advances in treatment strategies.
Recent Development Activities in the Urothelial Carcinoma Treatment Landscape
Request a sample and discover the recent advances in Urothelial Carcinoma Pipeline Ongoing Clinical Trial Analysis and Medications, click here @ Urothelial Carcinoma Pipeline Treatment Landscape
Urothelial Carcinoma Emerging Drugs Profile
Pemazyre (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test9. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.
Cetrelimab is a Janssen discovered and developed investigational programmed cell death receptor-1 (PD-1) monoclonal antibody being studied in the treatment of bladder cancer, prostate cancer, and multiple myeloma as a combination treatment. Cetrelimab is also being evaluated in multiple combination regimens across the Janssen oncology portfolio.
Urothelial Carcinoma Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the therapies for Urothelial Carcinoma. The companies which have their Urothelial Carcinoma drug candidates in the most advanced stage, i.e. Phase III include Janssen Research and Development.
For further information, refer to the detailed Urothelial Carcinoma Unmet Needs, Urothelial Carcinoma Market Drivers, and Market Barriers, click here for Urothelial Carcinoma Ongoing Clinical Trial Analysis
Scope of the Urothelial Carcinoma Pipeline Report
Dive deep into rich insights for drugs for Urothelial Carcinoma Market Drivers and Urothelial Carcinoma Market Barriers, click here @ Urothelial Carcinoma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Urothelial Carcinoma Mergers and acquisitions, Urothelial Carcinoma licensing activities @ Urothelial Carcinoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services